Amphastar P
$ 22.88
4.91%
17 Apr - close price
- Market Cap 989,523,000 USD
- Current Price $ 22.88
- High / Low $ 23.00 / 21.98
- Stock P/E 10.74
- Book Value 17.28
- EPS 2.03
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.13 %
- 52 Week High 31.26
- 52 Week Low 17.03
About
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.
Analyst Target Price
$28.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-04 | 2025-11-06 | 2025-08-07 | 2025-05-06 | 2025-02-26 | 2024-11-06 | 2024-08-07 | 2024-05-10 | 2024-02-29 | 2023-11-08 | 2023-08-08 | 2023-05-09 |
| Reported EPS | 0.73 | 0.93 | 0.85 | 0.74 | 0.92 | 0.96 | 0.94 | 1.04 | 0.88 | 1.15 | 0.65 | 0.62 |
| Estimated EPS | 0.9251 | 0.8277 | 0.74 | 0.6877 | 0.9383 | 1 | 0.77 | 0.96 | 0.93 | 0.69 | 0.56 | 0.48 |
| Surprise | -0.1951 | 0.1023 | 0.11 | 0.0523 | -0.0183 | -0.04 | 0.17 | 0.08 | -0.05 | 0.46 | 0.09 | 0.14 |
| Surprise Percentage | -21.0896% | 12.3596% | 14.8649% | 7.6051% | -1.9503% | -4% | 22.0779% | 8.3333% | -5.3763% | 66.6667% | 16.0714% | 29.1667% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.6 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AMPH
2026-04-15 23:40:26
Amphastar Pharmaceuticals provided updates on its growth drivers and pipeline at the Needham conference. The company expects Baqsimi sales to hit $175 million this year, triggering a significant milestone payment, despite some pricing pressure. Primatene Mist is projected for high single to low double-digit growth, while Amphastar also plans for new launches, including AMP-007 in early Q2 and key diabetes biosimilars in 2027.
2026-04-14 00:38:48
This article announces an SEC filing of type ARS for Amphastar Pharmaceuticals, Inc. (AMPH) on April 13, 2026. The filing has a low impact and neutral sentiment. The article provides details about the filing, links to the original document, and offers an overview of AMPH's stock data and recent news.
2026-04-12 00:39:12
The article title, "Do options traders know something about Amphastar Pharmaceuticals stock we don't?", suggests a market analysis focusing on Amphastar Pharmaceuticals (AMPH) and the implications of options trading activity. It hints at exploring whether unusual options market behavior might signal future stock movements or insider knowledge that the general public and other investors are not yet privy to. Without the full article, specific details about the nature of the options activity or the conclusions drawn are not available.
2026-04-09 12:09:50
Amphastar Pharmaceuticals, Inc. announced that its CFO, EVP of Regulatory Affairs and Clinical Operations, and SVP of Corporate Communication will present at the 25th Annual Needham Healthcare Conference on April 14, 2026. The presentation will be webcast live at 11:45 AM ET and available for replay for 30 days on the company's investor relations website. The biopharmaceutical company specializes in developing and commercializing generic and proprietary injectable, inhalation, and intranasal products, along with active pharmaceutical ingredients.
2026-04-08 22:09:06
This article provides a financial overview of Amphastar Pharmaceuticals, Inc (AMPH), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company's largest revenue contributor is "Other finished pharmaceutical products," and its gross margin stands at 46.79%. A competitive analysis against AKTS and PCRX is also presented.
2026-04-08 15:10:19
Barclays has lowered its price target for Amphastar Pharmaceuticals (NASDAQ:AMPH) to $23.00 from $30.00, maintaining an "equal weight" rating. This adjustment comes after the company recently missed quarterly earnings and revenue estimates. The new target implies a potential upside of approximately 12% from its previous close, with the stock currently holding an average "Hold" rating from analysts.
